MNPR
Monopar Therapeutics Inc

3,367
Mkt Cap
$620.73M
Volume
193,681.00
52W High
$105.00
52W Low
$13.94
PE Ratio
-25.90
MNPR Fundamentals
Price
$86.16
Prev Close
$85.67
Open
$85.45
50D MA
$68.68
Beta
0.97
Avg. Volume
62,781.95
EPS (Annual)
-$4.11
P/B
10.11
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 42.5% in Monopar Therapeutics (MNPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·11d ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
Zacks·5mo ago
News Placeholder
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics PR Newswire NORTH CHICAGO, Ill., Jan...
PR Newswire·9mo ago
News Placeholder
Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket
This biotech stock is a promising buy, but it does come with risks.
barchart.com·9mo ago
News Placeholder
Monopar Therapeutics, Energy Vault Holdings, FREYR Battery: 3 Stocks Retailers Are Most Bullish Thursday Afternoon
A micro-cap, clinical-stage biotech and two battery manufacturers elicited the most bullish reaction from retail traders.
Stocktwits·1y ago
News Placeholder
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder. read more...
Benzinga·1y ago
News Placeholder
Monopar Stock Skyrockets After Agreement With AstraZeneca's Unit On Wilson's Disease Drug: Retail On Cloud Nine
The company will be responsible for all future global development and commercialization activities.
Stocktwits·1y ago
News Placeholder
Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today
Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans. read more...
Benzinga·1y ago
News Placeholder
Monopar Therapeutics Inc: Positioned for Growth with Strategic Radiopharmaceutical Pivot and Promising Preclinical Data
JonesTrading analyst Justin Walsh reiterated a Buy rating on Monopar Therapeutics Inc (MNPR Research Report) today and set a price target of $2.0...
TipRanks Financial Blog·1y ago
News Placeholder
Monopar Therapeutics Begins Pioneering MNPR-101-Zr Trial
The latest announcement is out from Monopar Therapeutics Inc (MNPR). Monopar Therapeutics Inc. has reached a pivotal milestone by enrolling the fir...
TipRanks Financial Blog·1y ago

Latest MNPR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.